NeoGenomics Sees Q3 Revenue Of About $209M; Reiterates FY2026 Revenue, Adjusted EBITDA Guidance, Expects To Raise Revenue Guidance Midpoint On Q3 Call

NeoGenomics reported approximately $209 million in revenue for Q3. The company reiterated its revenue and adjusted EBITDA guidance for FY2026 and indicated that it expects to raise the revenue guidance midpoint during the Q3 earnings call.